United Therapeutics Corporation
UTHR
Rang în acțiuni
#1030
United Therapeutics Corporation, a biotechnology firm, is dedicated to... United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Preț acțiune
$533.18
Ultima sincronizare: 2026-10-16
Capitalizare de piață
$22.87B
Schimbare (1 zi)
-1.54%
Schimbare (1 an)
23.04%
Țară
US
Tranzacționează United Therapeutics Corporation (UTHR)
Categorie
Healthcare
Marja operațională pentru United Therapeutics Corporation (UTHR)
Marja operațională la October 2026 TTM: 44.49%
Conform celor mai recente rapoarte financiare și prețului acțiunilor United Therapeutics Corporation, marja operațională curentă (TTM) este 44.49%. La finalul anului 2023, compania avea o marjă operațională de 50.91%.
Istoricul marjei operaționale pentru United Therapeutics Corporation din 2000 până în 2026
Marja operațională la sfârșitul fiecărui an
| An | Marja Operațională | Schimbă |
|---|---|---|
| 2026 (TTM) | 44.49% | -7.04% |
| 2024 | 47.86% | -5.99% |
| 2023 | 50.91% | 0.61% |
| 2022 | 50.60% | 53.43% |
| 2021 | 32.98% | -17.59% |
| 2020 | 40.02% | -409.03% |
| 2019 | -12.95% | -126.17% |
| 2018 | 49.48% | 4.76% |
| 2017 | 47.23% | -28.88% |
| 2016 | 66.41% | 39.25% |
| 2015 | 47.69% | 14.04% |
| 2014 | 41.82% | 59.68% |
| 2013 | 26.19% | -43.10% |
| 2012 | 46.03% | 7.65% |
| 2011 | 42.76% | 57.44% |
| 2010 | 27.16% | 286.34% |
| 2009 | 7.03% | -124.12% |
| 2008 | -29.15% | -1,074.92% |
| 2007 | 2.99% | -83.54% |
| 2006 | 18.16% | -50.92% |
| 2005 | 37.00% | 106.13% |
| 2004 | 17.95% | -183.06% |
| 2003 | -21.61% | -63.84% |
| 2002 | -59.77% | -92.70% |
| 2001 | -818.93% | -79.41% |
| 2000 | -3,977.08% | 0.00% |
Marja operațională pentru companii similare sau concurente
| Companie | Marja Operațională | Diferență în marja operațională | Țara |
|---|---|---|---|
| 38.59% | -99.13% |
US
|
|
| -149.01% | -103.35% |
US
|
|
| 25.57% | -99.43% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.35% |
NL
|
Ce este marja operațională a unei companii?
Marja operațională este un indicator esențial pentru evaluarea profitabilității unei companii. Marjele operaționale mai mari sunt de obicei mai bune, deoarece arată că o companie poate vinde produsele sau serviciile sale la prețuri mult mai mari decât costurile de producție. Marja operațională se calculează împărțind profitul companiei la venitul său.